AIM
SLNO

AXA Investment Managers’s Soleno Therapeutics SLNO Stock Holding History

AXA Investment Managers’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$2.57M Buy
+38,037
New +$2.82M 0.01% 723

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AXA Investment Managers's SLNO Position: Q3 2025 in Review

AXA Investment Managers opened a new position in Soleno Therapeutics (SLNO) in Q3 2025: 38,037 shares worth $2.57M. The stake represents 0.01% of the portfolio and ranks #723 among its holdings.

240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • AXA Investment Managers held 38,037 shares of Soleno Therapeutics worth $2.57M as of Q3 2025.
  • Soleno Therapeutics was a new AXA Investment Managers position in Q3 2025.
  • Soleno Therapeutics made up 0.01% of AXA Investment Managers's portfolio in Q3 2025, its #723 holding.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.